07 Jul 2025
Lonza launches next generation 4D-Nucleofector® LV Unit PRO for improved electroporation in GMP manufacturing

  • Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing

  • New system includes optimized cartridge design for improved performance for CRISPR-based knock-out, knock-in and transposition

Basel, Switzerland, 7 July 2025 – Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of 4D-Nucleofector® LV Unit PRO, their next-generation large-scale electroporation unit designed to deliver clinically relevant cargos into large volumes of T cells. This unit builds on Lonza’s well-established non-viral large-scale transfection platform and is optimized for CRISPR-based genome engineering and other advanced cell therapy applications.

For more than twenty years, Lonza’s Nucleofector® Technology has been a cornerstone in cell and gene therapy R&D, enabling efficient delivery into hard-to-transfect primary cells, such as T cells. The newly introduced 4D-Nucleofector® LV Unit PRO further advances this technology, offering enhanced performance for CRISPR-based knock-out, knock-in and transposition.

A key innovation is the implementation of the new Nucleocuvette® Cartridges PRO, an improved cartridge version that enables the electroporation of complex cargos into up to one billion cells per run. The new cartridge supports complex clinically-relevant cargo delivery and introduces several usability improvements, including greater flexibility, simplified loading and clearing, and increased robustness of the flow-through process. The upgraded system is suited for preclinical studies and process development, serving as a scalable and reproducible platform for a seamless translation from discovery projects to GMP-compliant manufacturing for next-generation cell and gene therapies.

Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: “Lonza’s large-scale 4D-Nucleofector® LV Unit has been pivotal in supporting non-viral manufacturing of advanced therapy medicinal products. With the launch of the next-generation 4D-Nucleofector® LV Unit PRO, we are extending these capabilities to support GMP manufacturing across scales, enabling smoother process development and a seamless translation from R&D to clinical manufacture.”

Additional Information

To learn more about Lonza’s Bioscience offerings, visit bioscience.lonza.com
To learn more about the 4D-Nucleofector® LV Unit PRO, visit bioscience.lonza.com/large-scale-electroporation